Panelists discuss how ideal candidates for aflibercept 8 mg include patients with stable disease on current anti-VEGF therapy who seek reduced treatment burden, newly diagnosed patients, and those demonstrating good response to initial loading doses.
Video content above is prompted by the following:
Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.